Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Theravance Biopharma and Mylan COPD Product is Speeding Towards Approval

June 3, 2016 0

Enrollment has been completed in all the three ongoing clinical trials comprising the firm’s Phase 3 …

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

June 2, 2016 0

Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from …

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

May 27, 2016 0

Ionis Pharmaceuticals (IONS) stock plummeted when GlaxoSmithKline (GSK) stopped pursuing a late stage trial of Ionis-TTR …

Great News for Innoviva and COPD Patients

May 25, 2016 0

GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) …

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

May 23, 2016 0

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ …

Accelerated FDA Approvals of Immunotherapy Treatments Are Accelerating

May 19, 2016 0

CANCER Everyday something new is discovered that explains cancer behavior, including proliferation, response to treatment, resistance …

Portola: Solving the Huge Problem of the New Anticoagulants

May 18, 2016 0

Notwithstanding the unrelenting improvements being constantly made in managing blood coagulation’s problems, conventional anticoagulants still have …

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

May 17, 2016 0

COLLABORATIONS Preparing for the Future, Biogen Signs a Lucrative Collaborative Agreements While Highlighting the Small Firm …

Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. See Also: Underestimated Biotech Firms

May 16, 2016 0

Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells. AstraZeneca’s (AZN) Chief …

Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

May 13, 2016 0

Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of …

Giving to Gilead What Belongs to Gilead. Jazz Offers a Needed Relief

May 11, 2016 0

GILEAD After years of controversial refraining, official India reversed course and granted Gilead Sciences its patent …

Incyte Acquires Ariad Pharmaceuticals European Operations. See Also: A Great Achievement by Illumina

May 10, 2016 0

By June, which is next month, Incyte (INCY) will be the owner of the European operations …

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

May 9, 2016 0

EXELIXIS AGAIN They said: Sell EXEL, as no partner is interested in the firm’s FDA approved …

Prohost Letter #395

May 4, 2016 0

Prohost Letter #395 On the Road TO DEFEATING CANCER - Results of cancer treatment with novel immunotherapy …

A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

May 2, 2016 0

GILEAD SCIENCES The people who cause the selloff of Gilead’s (GILD) stock because it missed 5 …

Who Will End Up Acquiring Medivation? Abbott Acquires St Jude. See Also: Alnylam

April 28, 2016 0

Medivation is a Target for Acquisition The Question is: Who Will Acquire Medivation? Sanofi has made a bid …

Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL

April 27, 2016 0

Biotech NEWS AGENUS Agenus’ First Checkpoint Inhibitor to reach Clinical Trial The first patient has …

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

April 26, 2016 0

Congratulations. The FDA approved Exelixis’ (EXEL) drug Cabometyx™ (cabozantinib) tablets for advanced renal cell carcinoma …

TapImmune and Loxo Oncology Have Interesting News

April 25, 2016 0

The AACR 2016 meeting presentations differed substantially from previous meetings. The 2016 meeting has brought near …

Why Illumina Might Be Offering a Lucrative Investment Opportunity

April 21, 2016 0

Illumina Showing 6% revenue increase over the same quarter last year, Q1 2016, was not enough as Illumina …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Theravance Biopharma and Mylan COPD Product is Speeding Towards Approval

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

Great News for Innoviva and COPD Patients

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

Accelerated FDA Approvals of Immunotherapy Treatments Are Accelerating

Portola: Solving the Huge Problem of the New Anticoagulants

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. See Also: Underestimated Biotech Firms

Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

Giving to Gilead What Belongs to Gilead. Jazz Offers a Needed Relief

Incyte Acquires Ariad Pharmaceuticals European Operations. See Also: A Great Achievement by Illumina

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

Prohost Letter #395

A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

Who Will End Up Acquiring Medivation? Abbott Acquires St Jude. See Also: Alnylam

Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

TapImmune and Loxo Oncology Have Interesting News

Why Illumina Might Be Offering a Lucrative Investment Opportunity